The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein
product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 …

Over the past two decades, it was discovered that introducing synthetic small interfering
RNAs (siRNAs) into the cytoplasm facilitates effective gene-targeted silencing. This …

Cytosine base editors (CBEs) enable programmable genomic C· G-to-T· A transition
mutations and typically comprise a modified CRISPR–Cas enzyme, a naturally occurring …

Ischemic stroke is a leading cause of global mortality and long-term disability. However,
there is a paucity of whole-genome sequencing studies on ischemic stroke, resulting in …

Primarily a consequence of sedentary lifestyle, atherosclerosis has already reached
pandemic proportions, and with every year the burden of it is only increasing. As low-density …

Dyslipidemia is a major risk factor for stroke, following hypertension, diabetes, and smoking,
and is an important risk factor for the prevention and treatment of coronary artery disease …

Hypercholesterolemia plays a crucial role in the development of atherosclerosis, but it
remains an undertreated and underdiagnosed disease. Taking into consideration the high …

Background Inclisiran is a novel siRNA therapy that inhibits the synthesis of proprotein
convertase subtilisin-kexin type 9 (PCSK9) by targeting the PCSK9 mRNA, consequently …

Aims Pro-protein convertase subtilisin-kexin type 9 (PCSK9), which is expressed mainly in
the liver and at low levels in the heart, regulates cholesterol levels by directing low-density …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that promotes the
degradation of low-density lipoprotein receptors. It is involved in hyperlipidemia as well as …